Dendrimers with antiretroviral activity
-
1
Aristotle University of Thessaloniki, Department of Pharmacology, Greece
Dendrimers with antiretroviral activity are: PolyAmidoAmine (PAMAM) dendrimers, Poly-PropyleneImine (PPI) dendrimers, PEGylated Polylysine dendrimers and Polyanionic or Polysulfonate dendrimers. PAMAM dendrimers, covalently modified with naphthyl sulfonate residues on their surface, exhibit antiviral activity against HIV by inhibiting early stage virus/cell adsorption and later stage viral replication. PAMAM dendrimers interfere with reverse transcriptase and/or integrase enzyme activities. PAMAM dendrimers act against HIV-1LAI in primary human peripheral blood mononuclear cells (PBMCs), while they are cytotoxic in PBMCs, CEM and Vero cells. One drawback is that PAMAM dendrimers appear to have increased cytotoxicity. Polyanionic (Polysulfonate) dendrimers inhibit the replication of HIV. This can be achieved by interfering, either with virus adsorption or with the replication cycle of the virus. According to recent studies, these dendrimers are highly effective against HIV-1 IIIb strain. In addition to this, they are also effective against other HIV-1 strains, HIV-2 strains, simian immunodeficiency virus (SIV, strain MAC251) and HIV-1 strains that are resistant to reverse transcriptase inhibitors. Polylysine dendrimers, modified with sulfonated naphthyl groups or mannosyl surface groups, seem to be useful as antiviral drugs against HIV retrovirus. Polylysine dendrimers can reduce the transmission of HIV and other sexually transmitted diseases.
Keywords:
Dendrimers,
Retrovirus,
HIV,
PAMAM dendrimers,
Polylysine dendrimers
Conference:
8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010, Thessaloniki, Greece, 1 Oct - 5 Oct, 2010.
Presentation Type:
Poster
Topic:
Nanopharmacology / Nanomedicine
Citation:
Antonoglou
G and
Papaioannidou
P
(2010). Dendrimers with antiretroviral activity.
Front. Pharmacol.
Conference Abstract:
8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010.
doi: 10.3389/conf.fphar.2010.60.00101
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
28 Oct 2010;
Published Online:
04 Nov 2010.
*
Correspondence:
Dr. Paraskevi Papaioannidou, Aristotle University of Thessaloniki, Department of Pharmacology, Thessaloniki, Greece, ppap@auth.gr